Exhibit 99.1 Columbia Sportswear Company Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Full Year 2026 Financial Outlook Fourth Quarter 2025 Highlights Full Year 2025 Highlights Full Year 2026 Financial Outlook The following forward-looking statements reflect our expectations as of February 3, 2026 and are subject to significant risks and business uncertainties, including those factors described under "Forward-Looking Statements" below. Additional disclosures and financial outlook det ...

Digital Turbine Reports Fiscal 2026 Third Quarter Financial Results Third Quarter Revenue Totaled $151.4 Million, Representing Year-over-Year Growth of 12% Third Quarter GAAP Net Income of $5.1 Million and GAAP EPS of $0.03; Third Quarter Non-GAAP Adjusted Net Income of $21.7 Million and Non-GAAP Adjusted EPS of $0.18 1 1 Third Quarter Non-GAAP Adjusted EBITDA Totaled $38.8 Million, Representing Year-over-Year Growth of 76% 2 Austin, TX – February 3, 2026 – Digital Turbine, Inc. (Nasdaq: APPS) announced fin ...

Financial Performance - For Q4 2025, total revenues increased 9% to $9.9 billion compared to Q4 2024, with product sales growing 7% driven by 10% volume growth [3]. - For the full year 2025, total revenues increased 10% to $36.8 billion, with product sales also growing 10% due to 13% volume growth [3]. - GAAP EPS for Q4 2025 increased 111% to $2.45, while for the full year, it increased 88% to $14.23, driven by higher revenues and net unrealized gains [3]. - Non-GAAP EPS for the full year increased 10% to $21.84, despite higher operating expenses [8]. - Total product sales for Q4 2025 reached $9,367 million, a 7% increase from $8,716 million in Q4 2024 [17]. - Total product sales for FY 2025 were $35,148 million, a 10% increase from $32,026 million in FY 2024 [18]. - Net income for Q4 2025 was $1,333 million, compared to $627 million in Q4 2024, representing a 112.5% increase [67]. - Basic earnings per share for the full year 2025 were $14.33, compared to $7.62 in 2024, reflecting an increase of 88.5% [67]. - GAAP net income for Q4 2025 was $1,333 million, compared to $627 million in Q4 2024, representing a 112.5% increase [70]. - Non-GAAP net income for Q4 2025 was $2,875 million, slightly down from $2,879 million in Q4 2024, indicating a marginal decrease of 0.1% [71]. Cash Flow and Expenses - Free cash flow for 2025 was $8.1 billion, down from $10.4 billion in 2024, influenced by working capital timing and higher capital expenditures [8]. - In Q4 2025, the company reported total revenues of $1.0 billion in free cash flow, a decrease from $4.4 billion in Q4 2024, primarily due to working capital timing and higher capital expenditures [22]. - Total operating expenses for FY 2025 were $27.671 billion, a 6% increase from $26.166 billion in FY 2024 [24]. - Cash and cash equivalents decreased to $9,129 million as of December 31, 2025, down from $11,973 million in 2024 [68]. - Long-term debt decreased to $50,005 million in 2025 from $56,549 million in 2024 [68]. - The company generated $1,603 million in net cash from operating activities for Q4 2025, compared to $4,771 million for Q4 2024 [72]. - Free cash flow for the year ended December 31, 2025, was $8,100 million, down from $10,394 million in 2024 [72]. - Capital expenditures for the year ended December 31, 2025, were $1,858 million, compared to $1,096 million in 2024 [72]. Sales Performance by Product - Repatha sales increased 44% year-over-year to $870 million in Q4 2025, with a projected mid single-digit decline in net selling price for 2026 [9]. - UPLIZNA sales surged 131% year-over-year to $233 million in Q4 2025, primarily driven by volume growth [13]. - Enbrel sales decreased 48% year-over-year to $532 million in Q4 2025, impacted by lower net selling price and unfavorable changes to estimated sales deductions [13]. - Nplate sales increased 14% year-over-year to $385 million in Q4 2025, with U.S. government orders at $90 million compared to $128 million in 2024 [16]. - UPLIZNA sales surged by 73% year-over-year to $655 million in FY 2025, compared to $379 million in FY 2024 [18]. - TEZSPIRE sales increased by 52% year-over-year to $1,478 million in FY 2025, compared to $972 million in FY 2024 [18]. Research and Development - R&D expenses rose by 24% in Q4 2025, primarily due to increased spending on later-stage clinical programs, including MariTide [19]. - The company is conducting multiple Phase 3 studies for its product MariTide, targeting chronic weight management and Type 2 diabetes [27]. - The company plans to initiate Phase 3 studies of UPLIZNA in patients with autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy in 2026 [35]. - Dazodalibep and Daxdilimab are undergoing Phase 3 studies, with completion expected in H2 2026, targeting Sjögren's disease and primary discoid lupus erythematosus respectively [38]. - A Phase 3 study of TEZSPIRE is enrolling adults with moderate to very severe chronic obstructive pulmonary disease (COPD), with a baseline eosinophil count (BEC) of ≥ 150 cells/µl [41]. - IMDELLTRA received full FDA approval for treating extensive stage small cell lung cancer (ES-SCLC) and is involved in multiple ongoing Phase 1b and Phase 3 studies [44]. - Xaluritamig is in Phase 3 studies for metastatic castrate resistant prostate cancer (mCRPC), with various combinations and treatment settings being explored [48]. - A Phase 3 study of LUMAKRAS is enrolling patients with first-line KRAS G12C–mutated metastatic colorectal cancer, demonstrating ongoing commitment to oncology [55]. - The company is advancing a comprehensive clinical development program across various cancer treatments, reflecting its commitment to oncology innovation [44]. Future Projections - The company expects total revenues for 2026 to be in the range of $37.0 billion to $38.4 billion [27]. - For FY 2026, the company projects GAAP EPS in the range of $15.45 to $16.94 and non-GAAP EPS in the range of $21.60 to $23.00 [27]. - Capital expenditures for 2026 are expected to be approximately $2.6 billion [27]. - The company’s tax rate guidance for 2026 is projected to be between 15.5% and 17.5% [76]. - The GAAP diluted EPS guidance for the year ending December 31, 2026, is projected to be between $15.45 and $16.94 [74]. - Non-GAAP diluted EPS guidance for 2026 is estimated to be between $21.60 and $23.00, reflecting known adjustments of approximately $6.06 to $6.15 per share [74]. Debt and Equity - The company retired $6.0 billion of debt in FY 2025, reducing total debt outstanding to $54.6 billion as of December 31, 2025 [26]. - Amgen's total GAAP debt as of December 31, 2025, was $54,604 million, resulting in a debt leverage ratio of 3.2 [73]. - Total stockholders' equity increased to $8,658 million in 2025, up from $5,877 million in 2024 [68].

Exhibit 99.1 Media Relations: Constance Griffiths (949) 230-4867 Constance.Griffiths@skyworksinc.com Investor Relations: Raji Gill (949) 508-0973 Raji.Gill@skyworksinc.com Skyworks Delivers Strong Q1 FY26 Performance Driven by Mobile and Broad Markets IRVINE, Calif., Feb. 3, 2026 – Skyworks Solutions, Inc. (Nasdaq: SWKS), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, today reported first fiscal quarter results for the period ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Mercury Systems Reports Second Quarter Fiscal 2026 Results ANDOVER, Mass. February 3, 2026 Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), reported operating results for the second quarter of fiscal year 2026, ended December 26, 2025. "We delivered second quarter fiscal 2026 results that were ahead of our expectations, with solid year-over-year growth in backlog, revenue, and adjusted EBITDA, and robust free cash flow," said Bill Ballhaus, Mercury's Chairman and CEO. " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UY Scuti Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 39 E. Broadway, Suite 603 New York, New York 10002 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-42577 UY Scuti Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

FOR IMMEDIATE RELEASE CONTACTS: Tony Voorhees Michael Newman Chief Financial Officer Investor Relations Key Tronic Corporation StreetConnect (509)-927-5345 (206) 729-3625 KEY TRONIC CORPORATION ANNOUNCES RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2026 Significant Cost Reduction Initiatives in China and Mexico; Continued Program Wins; Positive Cash Flow from Operations Spokane Valley, WA— February 3, 2026 — Key Tronic Corporation (Nasdaq: KTCC), a provider of electronic manufacturing services (EMS), today ...

February 3, 2026 Dear Shareholders, In Q3 FY26, Cirrus Logic delivered revenue of $580.6 million and record GAAP and non-GAAP earnings per share of $2.66 and $2.97, respectively. Stronger-than-anticipated demand for our components shipping into smartphones and a favorable mix of end devices resulted in revenue above our guidance range. We also saw continued momentum in PCs, reflecting disciplined execution against our growth strategy during the quarter. Highlights include ramping our latest-generation ampli ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-08359 NEW JERSEY RESOURCES CORPORATION (Exact name of registrant as specified in its charter) New Jersey 22-2376465 (State or other jur ...